AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. HLXB
  4. [Form 3] Helix Acquisition Corp. II Initial Statement of Beneficial Ownership

[Form 3] Helix Acquisition Corp. II Initial Statement of Beneficial Ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3
Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. (BBOT) initial Form 3 filed for Pedro Beltran, the company's Chief Scientific Officer, discloses two stock option grants totaling 469,849 underlying shares. One option covers 443,298 shares exercisable starting 07/22/2034 at $4.17 per share; the second covers 26,551 shares exercisable starting 04/02/2035 at $7.88 per share. Vesting occurs in 1/48th monthly installments from May 1, 2024 and April 4, 2025 respectively. The filing date of the event is 08/11/2025.

BridgeBio Oncology Therapeutics, Inc. (BBOT) ha presentato il modulo iniziale Form 3 per Pedro Beltran, Chief Scientific Officer, rivelando due concessioni di opzioni su azioni che complessivamente coprono 469.849 azioni sottostanti. La prima opzione riguarda 443.298 azioni esercitabili a partire dal 22/07/2034 al prezzo di $4.17 per azione; la seconda riguarda 26.551 azioni esercitabili a partire dal 02/04/2035 al prezzo di $7.88 per azione. Le opzioni maturano in rate mensili pari a 1/48 a partire rispettivamente dal 1掳 maggio 2024 e dal 4 aprile 2025. La data del deposito dell'evento 猫 11/08/2025.

BridgeBio Oncology Therapeutics, Inc. (BBOT) present贸 el Formulario 3 inicial para Pedro Beltran, Director Cient铆fico, que revela dos concesiones de opciones sobre acciones por un total de 469.849 acciones subyacentes. Una opci贸n cubre 443.298 acciones ejercitables desde el 22/07/2034 a $4.17 por acci贸n; la segunda cubre 26.551 acciones ejercitables desde el 02/04/2035 a $7.88 por acci贸n. Las opciones se consolidan en cuotas mensuales de 1/48 a partir del 1 de mayo de 2024 y del 4 de abril de 2025, respectivamente. La fecha de presentaci贸n del evento es 11/08/2025.

BridgeBio Oncology Therapeutics, Inc. (BBOT)電� 斓滉碃 瓿柬暀 毂呾瀯鞛�(Chief Scientific Officer)鞚� Pedro Beltran鞐� 雽�頃� 齑堦赴 Form 3毳� 鞝滌稖頄堨溂氅�, 齑� 469,849欤检潣 旮办磮 欤检嫕鞚� 雽�靸侅溂搿� 頃橂姅 霊� 瓯挫潣 鞀ろ啞 鞓奠厴 攵�鞐ゼ 瓿店皽頄堨姷雼堧嫟. 頃橂倶鞚� 鞓奠厴鞚� 443,298欤茧 2034-07-22攵�韯� 欤茧嫻 $4.17鞐� 頄夓偓 臧�電ロ晿氅�; 霊� 氩堨Ц電� 26,551欤茧 2035-04-02攵�韯� 欤茧嫻 $7.88鞐� 頄夓偓 臧�電ロ暕雼堧嫟. 甓岆Μ電� 臧侁皝 2024雲� 5鞗� 1鞚缄臣 2025雲� 4鞗� 4鞚茧秬韯� 毵れ洈 1/48鞌� 氩犾姢韺呺惄雼堧嫟. 頃措嫻 靷贝鞚� 鞝滌稖鞚检潃 2025-08-11鞛呺媹雼�.

BridgeBio Oncology Therapeutics, Inc. (BBOT) a d茅pos茅 le Formulaire 3 initial pour Pedro Beltran, Chief Scientific Officer, r茅v茅lant deux attributions d'options sur actions repr茅sentant au total 469 849 actions sous-jacentes. La premi猫re option porte sur 443 298 actions exer莽ables 脿 partir du 22/07/2034 au prix de $4.17 par action ; la seconde porte sur 26 551 actions exer莽ables 脿 partir du 02/04/2035 au prix de $7.88 par action. La p茅riode d'acquisition s'effectue en versements mensuels de 1/48 脿 compter respectivement du 1er mai 2024 et du 4 avril 2025. La date de d茅p么t de l'茅v茅nement est le 11/08/2025.

BridgeBio Oncology Therapeutics, Inc. (BBOT) hat f眉r Pedro Beltran, den Chief Scientific Officer, das erstmalige Formular Form 3 eingereicht, das zwei Aktienoptionszuteilungen mit insgesamt 469.849 zugrunde liegenden Aktien offenlegt. Die erste Option umfasst 443.298 Aktien, aus眉bbar ab dem 22.07.2034 zu $4.17 je Aktie; die zweite umfasst 26.551 Aktien, aus眉bbar ab dem 02.04.2035 zu $7.88 je Aktie. Das Vesting erfolgt in monatlichen Raten von je 1/48 ab dem 1. Mai 2024 bzw. dem 4. April 2025. Das Datum der Einreichung des Vorgangs ist 11.08.2025.

Positive
  • None.
Negative
  • None.

Insights

TL;DR Reporting officer holds stock options totaling 469,849 shares with multi-year vesting; disclosure is routine and non-actionable.

The Form 3 documents initial beneficial ownership by the Chief Scientific Officer through two option grants with exercise prices of $4.17 and $7.88 and scheduled monthly vesting in 48 installments. For investors, this is standard insider compensation disclosure that increases transparency but does not by itself change company fundamentals.

TL;DR Standard Section 16 disclosure of executive equity awards; timing and vesting align with customary service-based grants.

The filing shows service-conditioned vesting schedules and clearly lists exercise prices and exercisable dates, satisfying regulatory disclosure. No departures, accelerated vesting, or unusual arrangements are disclosed. This is a routine governance disclosure reflecting equity-based incentive alignment.

BridgeBio Oncology Therapeutics, Inc. (BBOT) ha presentato il modulo iniziale Form 3 per Pedro Beltran, Chief Scientific Officer, rivelando due concessioni di opzioni su azioni che complessivamente coprono 469.849 azioni sottostanti. La prima opzione riguarda 443.298 azioni esercitabili a partire dal 22/07/2034 al prezzo di $4.17 per azione; la seconda riguarda 26.551 azioni esercitabili a partire dal 02/04/2035 al prezzo di $7.88 per azione. Le opzioni maturano in rate mensili pari a 1/48 a partire rispettivamente dal 1掳 maggio 2024 e dal 4 aprile 2025. La data del deposito dell'evento 猫 11/08/2025.

BridgeBio Oncology Therapeutics, Inc. (BBOT) present贸 el Formulario 3 inicial para Pedro Beltran, Director Cient铆fico, que revela dos concesiones de opciones sobre acciones por un total de 469.849 acciones subyacentes. Una opci贸n cubre 443.298 acciones ejercitables desde el 22/07/2034 a $4.17 por acci贸n; la segunda cubre 26.551 acciones ejercitables desde el 02/04/2035 a $7.88 por acci贸n. Las opciones se consolidan en cuotas mensuales de 1/48 a partir del 1 de mayo de 2024 y del 4 de abril de 2025, respectivamente. La fecha de presentaci贸n del evento es 11/08/2025.

BridgeBio Oncology Therapeutics, Inc. (BBOT)電� 斓滉碃 瓿柬暀 毂呾瀯鞛�(Chief Scientific Officer)鞚� Pedro Beltran鞐� 雽�頃� 齑堦赴 Form 3毳� 鞝滌稖頄堨溂氅�, 齑� 469,849欤检潣 旮办磮 欤检嫕鞚� 雽�靸侅溂搿� 頃橂姅 霊� 瓯挫潣 鞀ろ啞 鞓奠厴 攵�鞐ゼ 瓿店皽頄堨姷雼堧嫟. 頃橂倶鞚� 鞓奠厴鞚� 443,298欤茧 2034-07-22攵�韯� 欤茧嫻 $4.17鞐� 頄夓偓 臧�電ロ晿氅�; 霊� 氩堨Ц電� 26,551欤茧 2035-04-02攵�韯� 欤茧嫻 $7.88鞐� 頄夓偓 臧�電ロ暕雼堧嫟. 甓岆Μ電� 臧侁皝 2024雲� 5鞗� 1鞚缄臣 2025雲� 4鞗� 4鞚茧秬韯� 毵れ洈 1/48鞌� 氩犾姢韺呺惄雼堧嫟. 頃措嫻 靷贝鞚� 鞝滌稖鞚检潃 2025-08-11鞛呺媹雼�.

BridgeBio Oncology Therapeutics, Inc. (BBOT) a d茅pos茅 le Formulaire 3 initial pour Pedro Beltran, Chief Scientific Officer, r茅v茅lant deux attributions d'options sur actions repr茅sentant au total 469 849 actions sous-jacentes. La premi猫re option porte sur 443 298 actions exer莽ables 脿 partir du 22/07/2034 au prix de $4.17 par action ; la seconde porte sur 26 551 actions exer莽ables 脿 partir du 02/04/2035 au prix de $7.88 par action. La p茅riode d'acquisition s'effectue en versements mensuels de 1/48 脿 compter respectivement du 1er mai 2024 et du 4 avril 2025. La date de d茅p么t de l'茅v茅nement est le 11/08/2025.

BridgeBio Oncology Therapeutics, Inc. (BBOT) hat f眉r Pedro Beltran, den Chief Scientific Officer, das erstmalige Formular Form 3 eingereicht, das zwei Aktienoptionszuteilungen mit insgesamt 469.849 zugrunde liegenden Aktien offenlegt. Die erste Option umfasst 443.298 Aktien, aus眉bbar ab dem 22.07.2034 zu $4.17 je Aktie; die zweite umfasst 26.551 Aktien, aus眉bbar ab dem 02.04.2035 zu $7.88 je Aktie. Das Vesting erfolgt in monatlichen Raten von je 1/48 ab dem 1. Mai 2024 bzw. dem 4. April 2025. Das Datum der Einreichung des Vorgangs ist 11.08.2025.

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Beltran Pedro
(Last) (First) (Middle)
BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.
256 EAST GRAND AVENUE, SUITE 104
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
08/11/2025 		3. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Scientific Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) (1) 07/22/2034 Common Stock 443,298 $4.17 D
Stock Option (Right to Buy) (2) 04/02/2035 Common Stock 26,551 $7.88 D
Explanation of Responses:
1. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of May 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.
2. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 4, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Aaron Chan, Attorney-in-Fact 08/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What did Pedro Beltran disclose on the Form 3 for BBOT?

The Form 3 discloses two stock options covering 469,849 underlying shares: 443,298 exercisable from 07/22/2034 at $4.17, and 26,551 exercisable from 04/02/2035 at $7.88.

What is Pedro Beltran's role at BridgeBio Oncology Therapeutics (BBOT)?

He is listed as the company's Chief Scientific Officer on the Form 3.

When was the event requiring this Form 3 reported?

The date of the event requiring the statement is 08/11/2025, and the form shows a signature date of 08/18/2025 by attorney-in-fact Aaron Chan.

How do the options vest according to the filing?

Each option vests in equal monthly installments of 1/48th beginning on May 1, 2024 for the first grant and April 4, 2025 for the second, subject to continuous service.

Are there any unusual terms or immediate exercisable shares disclosed?

No unusual terms or accelerated vesting are disclosed; both grants follow standard time-based monthly vesting schedules.
Stock HLXB logo
Helix Acqsn II

NASDAQ:HLXB

HLXB Rankings

#4067 Ranked by Market Cap
N/A Ranked by Dividends

HLXB Latest News

Aug 6, 2025
Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics
Jul 11, 2025
Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business Combination
Feb 28, 2025
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3K伪-Targeting Medicines
Feb 14, 2024
Helix Acquisition Corp. II Announces Closing of $184 Million Initial Public Offering, Including the Full Exercise of the Underwriter';s Option to Purchase Additional Shares
Feb 9, 2024
Helix Acquisition Corp. II Announces Pricing of Upsized $160 Million Initial Public Offering

HLXB Latest SEC Filings

Sep 3, 2025
[SCHEDULE 13G] Helix Acquisition Corp. II SEC Filing
Aug 29, 2025
[S-1] Helix Acquisition Corp. II Files IPO Registration Statement
Aug 28, 2025
[Form 4] Helix Acquisition Corp. II Insider Trading Activity
Aug 28, 2025
[Form 4] Helix Acquisition Corp. II Insider Trading Activity
Aug 28, 2025
[Form 4] Helix Acquisition Corp. II Insider Trading Activity

HLXB Stock Data

232.74M
10.02M
44.89%
88.23%
0.06%
Shell Companies
Pharmaceutical Preparations
United States
BOSTON